Auro Laboratories Limited has submitted announcement for re-appointment of Internal Auditor.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Auro Laboratories' board, at its May 30, 2025 meeting, appointed Mr. Kuntal Pancholi (29+ years of experience in accounts and finance) as the new Chief Financial Officer and Key Managerial Personnel effective the same date. The board also appointed M/s. Pokharna and Associates, Chartered Accountants (FRN: 151048W) as Internal Auditors for FY 2025-26 (April 1, 2025 to March 31, 2026). It approved audited financial results for Q4 and FY ended March 31, 2025, which show full-year revenue from operations of Rs. 1,939.84 lakhs versus Rs. 5,363.52 lakhs in FY24 — a sharp decline of roughly 64%. Profit after tax for FY25 fell to Rs. 183.88 lakhs (EPS Rs. 2.95) from Rs. 779.21 lakhs (EPS Rs. 12.50) in FY24. The statutory auditor M/s. Kothari Jain & Associates issued a clean (unmodified) opinion on the results.
The steep year-on-year drop in revenue and profits is a negative signal for shareholders, but the clean audit opinion and fresh appointments of CFO and Internal Auditor point to stable governance. Note: the BSE headline mentions 're-appointment' of Internal Auditor, but the document describes a fresh appointment.